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Abstract
We describe a slowly progressive myopathy in 7 unrelated adult patients
with storage of polyglucosan in muscle fibers. Genetic investigation revealed
homozygous or compound heterozygous deleterious variants in the glycogenin-1
gene (GYG1). Most patients showed depletion of glycogenin-1 in skeletal muscle,
whereas 1 showed presence of glycogenin-1 lacking the C-terminal that normally
binds glycogen synthase. Our results indicate that either depletion of glycogenin-1
or impaired interaction with glycogen synthase underlies this new form of
glycogen storage disease that differs from a previously reported patient with
GYG1 mutations who showed profound glycogen depletion in skeletal muscle
and accumulation of glycogenin-1.
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We describe a slowly progressive myopathy in 7 unre-
lated adult patients with storage of polyglucosan in
muscle fibers. Genetic investigation revealed homozy-
gous or compound heterozygous deleterious variants in
the glycogenin-1 gene (GYG1). Most patients showed
depletion of glycogenin-1 in skeletal muscle, whereas 1
showed presence of glycogenin-1 lacking the C-terminal
that normally binds glycogen synthase. Our results indi-
cate that either depletion of glycogenin-1 or impaired
interaction with glycogen synthase underlies this new
form of glycogen storage disease that differs from a
previously reported patient with GYG1 mutations who
showed profound glycogen depletion in skeletal muscle
and accumulation of glycogenin-1.
ANN NEUROL 2014;76:891–898
Skeletal muscle relies on glycogen storage for contrac-tion and relaxation. Defects in glycogen synthesis or
degradation pathways provoke glycogen accumulation
and/or depletion, leading to energy deficiency.1
The 3 main enzymes involved in biosynthesis of
glycogen are glycogenin-1, glycogen synthase, and
branching enzyme.2 Glycogenin-1 is a glycosyltransferase
that forms a short glucose polymer of approximately 10
glucose residues by autoglucosylation. Glycogen synthase
and branching enzyme allow further elongation and
branching of the glucose polymer primer.2
Defects in various enzymes involved in glycogen
metabolism cause glycogen storage diseases. Some of
these are characterized by accumulation of polyglucosan,
which is variably resistant to digestion by alpha-amylase,
and contains abnormally long and poorly branched glu-
cosyl chains. Such diseases include branching enzyme
(GBE1) deficiency, phosphofructokinase deficiency, aden-
osine monophosphate–activated protein kinase deficiency,
and Lafora disease.1,3,4 Deficiency of RanBP-type and
C3HC4-type zinc finger–containing 1 (RBCK1) has
recently been shown to cause a polyglucosan storage dis-
ease with cardiomyopathy and skeletal myopathy.5
A specific mutation in the glycogenin-1 gene
(GYG1) has been shown to cause an impaired priming of
glycogen synthesis in 1 patient with cardiomyopathy and
depletion of glycogen in skeletal muscle.6,7
We describe a new polyglucosan body myopathy
due to pathogenic variants in GYG1.
Patients and Methods
Patients
Seven adult patients with polyglucosan body myopathy from 7
unrelated families of various ethnic backgrounds were included
in the present study. These patients belonged to a cohort of
some 20 patients with polyglucosan body myopathy and/or car-
diomyopathy negative for GBE1 and RBCK1 disease-causing
variants explaining the phenotype. After informed consent, the
patients underwent open biopsy of the deltoid or quadriceps
femoris muscle for morphologic and histochemical analyses of
fresh-frozen muscle tissue. Patients P5 and P6 have been previ-
ously reported.8
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Molecular Genetic Analysis
Genomic DNA was extracted from blood or frozen skeletal
muscle by standard methods, and Sanger sequencing was used
to screen for GYG1 (NM_004130) variants. Total RNA was
isolated from frozen skeletal muscle using the RNeasy Fibrous
Tissue Mini Kit (Qiagen, Valencia, CA). RNA was reverse-
transcribed with the QuantiTect reverse transcription kit (Qia-
gen), and GYG1 cDNA was analyzed by Sanger sequencing.
Morphological Analysis
Cryostat sections of fresh-frozen deltoid or quadriceps femoris
muscle tissue were histochemically analyzed by standard techni-
ques. For immunohistochemistry the following antibodies were
used: SQSTM1 (D-3; Santa Cruz Biotechnology, Santa Cruz,
CA; 1:1,000), Anti-Ubiquitin (P4D1-A11; Merck Millipore,
Billerica, MA; 1:100), and Anti-Human Desmin (D33; Dako
Cytomation, Carpinteria, CA; 1:50).
Protein and Functional Analyses
Autoglucosylation was analyzed in vitro applying a cell-free
protein expression system. The cloned sequence of glycogenin-
1 (NM_001184720) was inserted downstream of the 6xHis tag
in the pEXP5-NT/TOPO vector (Invitrogen Life Technologies,
Carlsbad, CA). Variants identified in the patients were intro-
duced using the QuikChange II site-directed mutagenesis kit
(Stratagene, La Jolla, CA) with the primers listed in the Supple-
mentary Table. The recombinant glycogenin-1 was expressed
using the FastLane Escherichia coli protein synthesis kit (RiNA,
Berlin, Germany) for 1 hour at 37C and allowed to autoglu-
cosylate in N-2-hydroxyethylpiperazine-N0-2-ethanesulfonic
acid (50mM, pH7.5), MnCl2 (5mM); dithiothreitol (0.5mM),
and 0.1M uridine diphosphate (UDP) glucose (Calbiochem,
San Diego, CA) for 1 hour at 30C.7,9
Western blot analysis was performed on protein extracted
from skeletal muscle tissue as well as recombinant protein.
Cryostat sections from biopsies were treated with 10lg/ml
human alpha amylase (Sigma-Aldrich, St Louis, MO) in a total
volume of 10ll phosphate-buffered saline, pH 6.5 for 1 hour
at 37C. Protein extracts were loaded and separated on 10%
Bis-Tris gel or 3 to 8% Tris-acetate Gel (Novex; Life Technolo-
gies, Grand Island, NY) followed by electroblotting. The mem-
branes were incubated with primary antihuman glycogenin-1
N-terminal antibody M07 clone 3B5 (Abnova, Taipei, Taiwan;
1:500) or C-terminal anti-GYG1 (Atlas Antibodies, Stockholm,
Sweden; 1:500) or anti-GBE1 (Atlas Antibodies; 1:500) or
anti-GYS1 (Atlas Antibodies). Western Breeze (Invitrogen) was
used for antibody detection.
Results
Clinical Findings
A clinical summary is provided in the Table. Age at
onset ranged from childhood to adult life. Muscle weak-
ness was progressive in 1 patient and slowly progressive
in the other patients. Four patients developed symmetri-
cal proximodistal muscle weakness with variableT
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involvement of hip and shoulder girdle muscles, lower
legs, and hand muscles. Two patients showed isolated
proximal muscle weakness. One patient showed only
hand and finger involvement starting in adulthood.
Facial and ocular muscles were spared. Serum creatine
kinase was elevated in 1 and normal in the other
patients. Electromyography was invariably myopathic,
but 1 patient showed in addition neurogenic involve-
ment. Electrocardiography and cardiac ultrasound were
normal in all patients. Cardiac magnetic resonance imag-
ing was normal in P4. Myocardial biopsy was not
performed.
Morphological Analysis
Morphological investigations by light- and electron-
microscopy of muscle revealed characteristic alterations.
Thirty to forty percent of the fibers, frequently in clus-
ters, showed inclusions in the center and subsarcolemmal
regions of the fibers (Fig 1). Periodic acid–Schiff (PAS)-
positive material formed the main content of the inclu-
sions. Some fibers presented inclusions surrounded by
normal glycogen content, whereas other fibers showed
depletion of normal glycogen around the inclusions.
Alpha-amylase treatment showed a variable degree of
digestion of the PAS-positive material. Inclusions were
positively immunostained for desmin, ubiquitin-binding
protein sequestosome-1 (p62/SQSTM1), and ubiquitin.
Electron microscopy demonstrated presence of storage
material in the subsarcolemmal and central regions of the
fibers. The inclusions frequently formed a lobulated
grape structure composed of oval subunits with the same
electron density. A rim of normal glycogen particles and
mitochondria surrounded the storage material. Smaller
inclusions often contained central areas composed of less
electron-dense filamentous material. Necrotic or regener-
ating fibers were not identified. Increase of interstitial
connective tissue and fat was noted in P3 and P5, and
more pronounced in P7.
Molecular Genetic Analysis
The identified GYG1 pathogenic variants are summarized
in the Table and Figure 2A. The most common variant
was a single nucleotide substitution at the donor splice
site in intron 2 (c.14313G>C), either homozygous or
compound heterozygous. Analysis of GYG1 cDNA with
this variant revealed aberrant splicing with skipping of
exon 2 (r.8_143del) creating a frameshift p.Asp3Glufs*4
(see Fig 2B–E). P5 was compound heterozygous for the
common splice site variant and a c.7G>C variant affect-
ing the last nucleotide in exon 1, within the donor splice
site. The corresponding transcript was not detected in
cDNA, suggesting that this allele was not expressed. P7
was compound heterozygous for the common splice site
variant and a C-terminal nonsense (c.970C>T,
p.Arg324*) variant. P3 was compound heterozygous for a
missense (c.304G>C, p.Asp102His) and a nonsense
(c.749G>A, p.Trp250*) variant. P4 was homozygous for
a N-terminal missense variant (c.46G>C, p.Ala16Pro)
that was confirmed at the RNA level. P6 was homozy-
gous for a single nucleotide deletion (c.484delG), and no
transcript was detected in cDNA.
Protein and Functional Analyses
Expression of glycogenin-1 in skeletal muscle tissue was
studied by Western blot analysis either without or with
alpha-amylase treatment, to cleave off the glucose in the
glycogen particles (see Fig 2F). Free autoglucosylated
glycogenin-1 weighs approximately 1kDa more than the
unglucosylated protein. In normal individuals, there is no
free glycogenin-1. A weak band corresponding to
glycogenin-1 was identified in P1 and P5 only after
alpha-amylase treatment, demonstrating presence of some
residual functional glycogenin-1. P4 and P6 did not
show any glycogenin-1. Glycogenin-1 was detected both
with and without alpha-amylase treatment in P7.
Glycogenin-1 had a reduced molecular weight in P7, cor-
responding to a shorter protein produced by the truncat-
ing variant c.970C>T p.Arg324*. The gel shift induced
by alpha-amylase treatment revealed that the protein was
functionally active with regard to autoglucosylation.
Material from P2 and P3 was not available for Western
blot analysis.
A gel shift after alpha-amylase treatment was identi-
fied only in P7, lacking the C-terminal of glycogenin-1
(see Fig 2F), suggesting defective elongation of the glu-
cose polymer primer. To further explore this hypothesis,
an additional Western blot experiment of glycogenin-1
was performed. Samples from P7 and a patient lacking
glycogen synthase due to GYS1 nonsense variants were
analyzed (see Fig 2G). In both cases, a gel shift of similar
size after alpha-amylase treatment was demonstrated.
These results suggest that elongation of the glycogen
polymer, normally catalyzed by glycogen synthase, was
impaired in P7 by loss of the glycogenin-1 C-terminal.
Western blot analyses for glycogen synthase and branch-
ing enzyme showed no changes in the expression in the
patients (see Fig 2H).
Assay of autoglucosylation in vitro of the GYG1
variants resulting in p.Trp250*, p.Asp102His, and
p.Ala16Pro did not show any gel shift after the addition
of UDP glucose, suggesting nonfunctional glycogenin-1
(see Fig 2I). Proteins with the missense variants were
detected with double bands even in the absence of UDP
glucose, suggesting that the shift was due to a
ANNALS of Neurology
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conformational change and not incorporation of glucose.
The C-terminal nonsense variant p.Arg324* resulted in
truncated protein with reduced molecular weight but pre-
served autoglucosylation, which was in accordance with
the results from Western blot analysis of glycogenin-1 in
patients’ muscle tissue (see Fig 2F).
Discussion
In the present study, we report a new recessive muscle
glycogen storage disorder caused by GYG1 pathogenic
variants. All patients presented a skeletal myopathy with-
out cardiac involvement. Most patients manifested slowly
progressive, adulthood onset, hip girdle, shoulder girdle,
FIGURE 1: Characteristic morphological alterations of skeletal muscle. (A) Hematoxylin–eosin (HE) staining showing bluish inclu-
sions in muscle fibers (arrows). (B) The inclusions contain periodic acid–Schiff (PAS)-positive material (arrows), and some fibers
lack normal intermyofibrillar glycogen (asterisk). (C) The storage material is partially resistant to alpha-amylase treatment
(arrows). (D–F) The storage material (arrows) is stained with antibodies for desmin, P62/SQSTM1, and ubiquitin. Scale bars in
A–F correspond to 5mm. (G, H) Electron microscopy demonstrating abnormal glycogen presenting with ovoid structures com-
posed of partly filamentous material surrounded by a rim of more dense glycogen granules and mitochondria.
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FIGURE 2: Genetic and protein analyses. (A) Schematic illustration of the coding and noncoding region of the gene GYG1
(NM_004130). Detected variants are marked in different colors for each patient (P1, light blue; P2, green; P3, orange; P4, red;
P5, yellow; P6, purple; P7, dark blue). (B) Reverse transcriptase polymerase chain reaction products covering exons 1 to 4. Lane
1: size ladder; lane 2: control sample with wild-type sequence; lane 3: patient homozygous for the GYG1 c.14313G>C variant
resulting in transcripts with skipping of exon 2; lane 4: patient heterozygous for the GYG1 c.14313G>C variant, showing 2
bands, 1 of normal size and 1 with aberrant splicing with exon 2 skipping (lower band). (C) Schematic illustration of the conse-
quences of incorrect splicing. The GYG1 c.14313G>C variant results in skipping of exon 2. (D) Normally spliced transcript. (E)
Aberrantly spliced transcript with exon 2 skipping. (F) Results of Western blot analysis of glycogenin-1 in skeletal muscle from a
normal control (WT) and patients (P1, P4, P5, P6, and P7) performed with (1) and without (2) alpha-amylase treatment. After
alpha-amylase treatment, glycogenin-1 was detected in P1, P5, and P7, demonstrating that these patients produce some residual
glycogenin-1. Without alpha-amylase treatment, free glycogenin-1 was detected in P7. (G) Western blot analysis of a normal con-
trol, P7, and a patient with glycogen synthase deficiency. The glycogenin-1 detected in P7 as well as in the glycogen synthase–
deficient patient revealed a gel shift corresponding to approximately 1kDa, indicating that it was autoglucosylated. Glycogenin-1
in P7 is reduced in size due to the truncating variant. (H) Western blot analyses of glycogen synthase (GYS1) and branching
enzyme (GBE1) in P1, P4, P5, P6, P7, 1 patient with GYS1 deficiency, and 1 with RBCK1 deficiency. No obvious upregulation or
downregulation of these enzymes was evident in patients with pathogenic GYG1 variants. (I) In vitro autoglucosylation demon-
strated that glycogenin-1 in P3 and P4 was unable to autoglucosylate when uridine diphosphate (UDP) glucose was added (1).
The truncated glycogenin-1 in P7 increased in size when UDP glucose was added, showing that it was autoglucosylated.
and/or hand and leg muscle weakness. One patient
showed childhood onset, and 1 presented a peculiar phe-
notype characterized by late onset weakness of hands and
fingers.
In the 7 patients, we identified different missense,
nonsense, or frameshift GYG1 pathogenic variants, distrib-
uted all over the gene. There was either reduced or com-
plete absence of glyogenin-1 protein, in accordance with
the deleterious effects of the variants. The most frequent
variant was c.14313G>C, identified in 4 patients from
different ethnic backgrounds. This common splice site vari-
ant caused a complete or nearly complete alternative splic-
ing, with profound reduction of wild-type glycogenin-1.
PAS-positive storage material was found in around
30 to 40% of muscle fibers. This picture had some simi-
larities with polyglucosan body myopathies of other
causes, especially branching enzyme or RBCK1 defi-
ciency.5,10,11 However, the inclusions found in
glycogenin-1–deficient patients appeared to be less alpha-
amylase resistant. These were also more frequently found
in fibers with apparently normal glycogen content com-
pared to myopathy associated with GBE1 and RBCK1.
These findings suggest morphological heterogeneity in
polyglucosan body myopathies and probably reflect the
differences in primary gene defects. Polyglucosan body
formation has in some cases been suggested to be caused by
an imbalance between the activities of glycogen synthase
and branching enzyme.12,13 We did not show any apparent
upregulation or downregulation of glycogen synthase or
branching enzyme in our glycogenin-1–deficient patients.
However, analysis of glycogen synthase and branching
enzyme activities were not available for our patients.
Unlike our patients, a previously reported patient
with pathogenic GYG1 variants showed cardiomyopathy
with storage of abnormal glycogen in cardiomyocytes and
glycogen depletion in skeletal muscle.6 This subject pre-
sented a different phenotype compared to our patients.
He showed a cardiomyopathy at young age, whereas our
patients developed late onset skeletal myopathy. His mus-
cle biopsy demonstrated profound glycogen depletion,
whereas our patients showed polyglucosan body myopa-
thy. Glycogenin-1 was accumulated in the previous
patients but depleted in ours. The type of pathogenic
variant and other possible factors might explain these
differences. Further studies may demonstrate a large
variability with regard to cardiac and skeletal muscle
involvement in patients with GYG1 pathogenic variants.
Various amounts of normal glycogen were found in
all patients despite depletion or absence of glycogenin-1.
This observation raises the question how this glycogen is
formed. Apparently, glycogenin-1 is not mandatory for
glycogen formation in muscle, which may explain the
relatively late onset and the slow progression of the
disease. Whether this is due to upregulation of another
autoglucosylating protein, or alternative primers for
glycogen synthase, remains to be investigated.
In P7, with glycogenin-1 lacking the C-terminal,
we demonstrated free autoglucosylated glycogenin-1.
This is similar to what is found in patients with glycogen
synthase deficiency.14 Because glycogen synthase is
known to bind the glycogenin-1 C-terminal,15 our results
strongly indicate that this binding is essential for glyco-
gen synthase function.
In summary, we have described a new muscle glyco-
gen storage disorder characterized by polyglucosan bodies
that is due to deficiency of glycogenin-1, and have shown
that the C-terminal of glycogenin-1 is essential for glyco-
gen synthase activity.
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